Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX)

On March 4, 2026, Piper Sandler expert Patrick Soon-Shiong accrued ImmunityBio, Inc. (NASDAQ:IBRX)'s terms nonsubjective to $12 from $7, maintaining an Overweight rating. The steadfast pointed retired ANKTIVA's beardown commercialized momentum, reporting U.S. nett revenues of astir $113 cardinal successful 2025, noting a astir 700% increase. Piper Sandler present forecasts ANKTIVA gross of $195 cardinal successful 2026, showing that request for the company's immunotherapy attraction remains strong.

On February 26, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) concluded enrollment successful the Phase 2 QUILT 2.005 randomized study, which compared ANKTIVA + Bacillus Calmette-Guérin (BCG) to BCG unsocial successful patients with BCG-naïve non-muscle invasive bladder crab carcinoma successful situ. The proceedings enrolled 366 patients and randomly assigned them to the 2 therapy groups up of schedule. An interim reappraisal conducted by the US Food and Drug Administration recovered that the combined therapy accrued the durability of implicit response, with 85% of patients retaining effect astatine six months compared to 57% for BCG alone, and 84% astatine 9 months versus 52%. The steadfast plans to taxable a biologics licensing exertion successful the 4th fourth of 2026.

ImmunityBio, Inc. (NASDAQ:IBRX) is simply a clinical-stage immunotherapy business. It creates next-generation treatments that activate immunogenic pathways to combat crab and infectious diseases.

While we admit the imaginable of IBRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Best Electric Utility Stocks to Invest In Now and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026.

Disclosure: None. Follow Insider Monkey connected Google News.